Insight Molecular Diagnostics Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $4.1M | $1.9M | $1.5M | $958.0K | $2.2M | $1.2M | — |
| Cost of Revenue | — | $1.8M | $1.1M | $1.0M | $880.0K | $697.0K | $1.9M | — |
| Gross Profit | — | $2.3M | $740.0K | $413.0K | $-18.0K | $1.4M | $-639.0K | — |
| Gross Margin | — | 56.7% | 39.3% | 27.5% | -1.9% | 64.6% | -52.5% | — |
| Operating Expenses | ||||||||
| Research & Development | — | $15.9M | $9.8M | $9.3M | $7.3M | $5.0M | $9.8M | $6.8M |
| SG&A Expense | — | $10.6M | $10.2M | $11.2M | $21.9M | $22.3M | $16.8M | $13.3M |
| Operating Income | — | $-51.1M | $-61.0M | $-25.1M | $-18.0M | $-53.7M | $-29.7M | $-22.2M |
| Operating Margin | — | -1,260.8% | -3,245.1% | -1,672.4% | -1,878.6% | -2,444.3% | -2,443.3% | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | $-60.7M | $-24.9M | $-18.6M | $-52.9M | $-31.2M | $-22.4M |
| Income Tax Expense | — | $0 | $0 | $0 | — | $-9.3M | $-1.3M | — |
| Net Income | — | $-50.2M | $-60.7M | $-27.8M | $-72.9M | $-64.1M | $-29.9M | $-22.4M |
| Net Margin | — | -1,238.5% | -3,225.0% | -1,848.4% | -7,609.8% | -2,916.2% | -2,461.5% | — |
| EPS (Basic) | — | $-1.65 | $-2.33 | $-1.88 | $-6.63 | $-0.01 | $0.00 | $0.00 |
| EPS (Diluted) | — | $-1.65 | $-2.33 | $-1.88 | $-6.63 | $-0.01 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | 32.2M | 30.5M | 26.1M | 15.3M | 11.1M | 11.0M | 8.57B | 7.07B |
| Shares Outstanding (Diluted) | 32.2M | 30.5M | 26.1M | 15.3M | 11.1M | 11.0M | 8.57B | 7.07B |
| Dividends Per Share | — | — | — | — | — | — | — | — |